Puma Biotech Reports $362M Revenue, $881M Net Loss for 2024
Ticker: PBYI · Form: 10-K · Filed: Feb 27, 2025 · CIK: 1401667
| Field | Detail |
|---|---|
| Company | Puma Biotechnology, Inc. (PBYI) |
| Form Type | 10-K |
| Filed Date | Feb 27, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: earnings, financials, biotech, loss
TL;DR
Puma Biotech 2024: $362M revenue, but a massive $881M net loss. Ouch.
AI Summary
Puma Biotechnology, Inc. filed its 2024 10-K on February 27, 2025, reporting total assets of $491.06 million and total liabilities of $47.65 million as of December 31, 2024. The company's net revenue for the fiscal year 2024 was $362 million, with a net loss of $881 million. Puma Biotechnology is primarily engaged in the development and commercialization of innovative cancer therapies.
Why It Matters
This filing provides a comprehensive overview of Puma Biotechnology's financial health and performance for the fiscal year 2024, which is crucial for investors to assess the company's stability and future prospects in the competitive biopharmaceutical market.
Risk Assessment
Risk Level: high — The company reported a significant net loss of $881 million on $362 million in revenue for fiscal year 2024, indicating substantial financial challenges.
Key Numbers
- $362M — Net Revenue (FY 2024) (Indicates the company's top-line performance for the year.)
- $881M — Net Loss (FY 2024) (Highlights significant expenses or lower-than-expected profitability.)
- $491.06B — Total Assets (as of 12/31/2024) (Represents the company's total resources.)
- $47.65M — Total Liabilities (as of 12/31/2024) (Represents the company's total obligations.)
Key Players & Entities
- PUMA BIOTECHNOLOGY, INC. (company) — Filer
- 2024-12-31 (date) — Fiscal Year End
- 2025-02-27 (date) — Filing Date
- $491,058,34 (dollar_amount) — Total Assets as of December 31, 2024
- $47,646,787 (dollar_amount) — Total Liabilities as of December 31, 2024
- $362,000,000 (dollar_amount) — Net Revenue for Fiscal Year 2024
- $881,000,000 (dollar_amount) — Net Loss for Fiscal Year 2024
FAQ
What were Puma Biotechnology's total revenues for the fiscal year ended December 31, 2024?
Puma Biotechnology reported total net revenues of $362 million for the fiscal year ended December 31, 2024.
What was Puma Biotechnology's net loss for the fiscal year ended December 31, 2024?
The company reported a net loss of $881 million for the fiscal year ended December 31, 2024.
What were Puma Biotechnology's total assets as of December 31, 2024?
As of December 31, 2024, Puma Biotechnology had total assets of $491,058,34.
What were Puma Biotechnology's total liabilities as of December 31, 2024?
As of December 31, 2024, Puma Biotechnology had total liabilities of $47,646,787.
What is Puma Biotechnology's primary business focus?
Puma Biotechnology, Inc. is focused on the development and commercialization of innovative cancer therapies.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 27, 2025 regarding PUMA BIOTECHNOLOGY, INC. (PBYI).